22.120.05% ( +0.01 )
Delay Opening Auction: Nov 13, 09:25:00Overview
NHWA (002262)
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 22.11
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 25.30
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 17.96
- Float Mkt Cap
- 22.34B
- Market CapCNY
- 22.41B
- P/ETTM
- 20.42
- P/EDynamic
- 14.66
- P/EStatic
- --
- EPSTTM
- 1.08
- EPSDynamic
- 1.51
- EPSStatic
- --
- BVPS
- 8.69
- P/B
- 2.55
- Circulating Supply
- 1.01B
- Dividend YieldTTM
- 1.81%
- DividendTTM
- 0.40
- Shares
- 1.01B
- Min lot size
- 100
- Currency
- CNY
NHWA Analyst Rating
View moreForecast & Rating
Oct 30, 2026Price forecast
¥28.1226.62%
Forecast & RatingBuy
4analysts
- Strong buy50.00%
- Buy25.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 1
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
News
MSN · Consensus price target for Jiangsu Nhwa Pharmaceutical Co. decreased by 10.24% to CN¥27.71
Zhitong · NHWA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.106 billion yuan, a year-on-year increase of 8.42%
Zhitong · NHWA: The hydrochloride of Tizanidine tablets has obtained a drug registration certificate
Zhitong · Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up
Zhitong · NHWA Investment establishes a pet supplies company
